Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F A Dorr

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
British Journal of Cancer|December 18, 2001
Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancerF McPhillips, P Mullen, B P Monia, et al.
Alimentary Pharmacology & Therapeutics|September 25, 2002
Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's diseaseB R Yacyshyn, C Barish, J Goff, et al.
Seminars in Oncology|October 1, 1994
Prognostic factors in stage D2 prostate cancer; important implications for future trials: results of a cooperative intergroup study (INT.0036). The National Cancer Institute Intergroup Study #0036M A Eisenberger, E D Crawford, M Wolf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2000
c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A)P J O'Dwyer, J P Stevenson, M Gallagher, et al.
The New England Journal of Medicine|August 17, 1989
A controlled trial of leuprolide with and without flutamide in prostatic carcinomaE D Crawford, M A Eisenberger, D G McLeod, et al.
Cancer|September 1, 1990
Leuprolide with and without flutamide in advanced prostate cancerE D Crawford, B A Blumenstein, P J Goodman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1995
Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalationD A Rinaldi, H A Burris, F A Dorr, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A)J P Stevenson, K S Yao, M Gallagher, et al.
Cancer Chemotherapy and Pharmacology|September 29, 1999
A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalationD A Rinaldi, J G Kuhn, H A Burris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2001
Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancerC M Rudin, J Holmlund, G F Fleming, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
British Journal of Cancer|December 18, 2001
Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancerF McPhillips, P Mullen, B P Monia, et al.
Alimentary Pharmacology & Therapeutics|September 25, 2002
Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's diseaseB R Yacyshyn, C Barish, J Goff, et al.
Seminars in Oncology|October 1, 1994
Prognostic factors in stage D2 prostate cancer; important implications for future trials: results of a cooperative intergroup study (INT.0036). The National Cancer Institute Intergroup Study #0036M A Eisenberger, E D Crawford, M Wolf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2000
c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A)P J O'Dwyer, J P Stevenson, M Gallagher, et al.
The New England Journal of Medicine|August 17, 1989
A controlled trial of leuprolide with and without flutamide in prostatic carcinomaE D Crawford, M A Eisenberger, D G McLeod, et al.
Cancer|September 1, 1990
Leuprolide with and without flutamide in advanced prostate cancerE D Crawford, B A Blumenstein, P J Goodman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1995
Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalationD A Rinaldi, H A Burris, F A Dorr, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A)J P Stevenson, K S Yao, M Gallagher, et al.
Cancer Chemotherapy and Pharmacology|September 29, 1999
A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalationD A Rinaldi, J G Kuhn, H A Burris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2001
Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancerC M Rudin, J Holmlund, G F Fleming, et al.
Pageof 4